Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytes

Affiliations

• ¹ Division of Oncology, University Hospital of Patras "Panagia the Help", University of Patras, Patras, Greece; Molecular Oncology Laboratory, Department of Medicine, University of Patras, Patras, Greece. Electronic address: [email protected].
• ² Department of Pathology, Ioannina University Hospital, Ioannina, Greece; Department of Pathology, German Oncology Center, Limassol, Cyprus.
• ³ Section of Biostatistics, Hellenic Cooperative Oncology Group, Data Office, Athens, Greece.
• ⁴ Laboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, Larissa, Greece.
• ⁵ Department of Pathology, Ioannina University Hospital, Ioannina, Greece.
• ⁶ Department of Pathology, University Hospital of Patras, Rion, Greece.
• ⁷ Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece; Department of Biomedical Sciences, School of Health Sciences, International Hellenic University, Thessaloniki, Greece.
• ⁸ Department of Pathology, Henry Dunant Hospital, Athens, Greece.
• ⁹ Department of Pathology, Metaxas Cancer Hospital, Piraeus, Greece.
• ¹⁰ Department of Pathology, Aristotle University of Thessaloniki, School of Health Sciences, Faculty of Medicine, Thessaloniki, Greece.
• ¹¹ Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece.
• ¹² Department of Pathology, Alexandra Hospital, Athens, Greece.
• ¹³ Department of Histopathology, Agii Anargiri Hospital, Athens, Greece.
• ¹⁴ Department of Anatomy-Histology-Embryology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.
• ¹⁵ Department of Medical Oncology, Medical School, University of Ioannina, Ioannina, Greece.
• ¹⁶ Second Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece.
• ¹⁷ Second Department of Medical Oncology, Metropolitan Hospital, Piraeus, Greece.
• ¹⁸ Third Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece.
• ¹⁹ Section of Medical Oncology, Department of Internal Medicine, Attikon University Hospital, Faculty of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
• ²⁰ Oncology Section, Second Department of Internal Medicine, Hippokratio Hospital, Athens, Greece.
• ²¹ First Department of Medical Oncology, Metropolitan Hospital, Piraeus, Greece.
• ²² Hematology-Oncology Unit, Fourth Department of Internal Medicine, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Greece.
• ²³ Oncology Department, General Hospital of Chania, Crete, Greece.
• ²⁴ Third Department of Medical Oncology, Hygeia Hospital, Athens, Greece.
• ²⁵ Department of Medical Oncology, 424 Army General Hospital, Thessaloniki, Greece.
• ²⁶ Division of Oncology, University Hospital of Patras "Panagia the Help", University of Patras, Patras, Greece.
• ²⁷ Department of Clinical Therapeutics, Alexandra Hospital, National Andistrian U Kapodniversity of Athens School of Medicine, Athens, Greece.
• ²⁸ First Department of Medicine, Laiko General Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
• ²⁹ Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece; Aristotle University of Thessaloniki, Thessaloniki, Greece; Department of Medical Oncology, German Oncology Center, Limassol, Cyprus.